Inhibition of adenylate cyclase by tetraplatin.

B. T. Ho; Y. Y. Huo; J. H. Lee; V. A. Levin

doi:10.1097/00001813-199106000-00007

Inhibition of adenylate cyclase by tetraplatin.

B. T. Ho, Y. Y. Huo, J. H. Lee, V. A. Levin

Neuro-Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In the investigation of effects of platinum-containing compounds on dopamine (DA)-activated adenylate cyclase system, tetraplatin and cisplatin were found to suppress the increase of enzyme activity by various activators. However, tetraplatin was a much more potent inhibitor than cisplatin, with its I50 values being 1/25, 1/45, and 1/130 that of cisplatin in the presence of DA/Gpp(NH)p, NaF/AlCl3, and forskolin/Gpp(NH)p respectively.

Original language	English (US)
Pages (from-to)	267-268
Number of pages	2
Journal	Anti-cancer drugs
Volume	2
Issue number	3
DOIs	https://doi.org/10.1097/00001813-199106000-00007
State	Published - Jun 1991

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)
Cancer Research

Access to Document

10.1097/00001813-199106000-00007

Cite this

@article{becb9ada8d5142bf84955838b51a2cff,

title = "Inhibition of adenylate cyclase by tetraplatin.",

abstract = "In the investigation of effects of platinum-containing compounds on dopamine (DA)-activated adenylate cyclase system, tetraplatin and cisplatin were found to suppress the increase of enzyme activity by various activators. However, tetraplatin was a much more potent inhibitor than cisplatin, with its I50 values being 1/25, 1/45, and 1/130 that of cisplatin in the presence of DA/Gpp(NH)p, NaF/AlCl3, and forskolin/Gpp(NH)p respectively.",

author = "Ho, {B. T.} and Huo, {Y. Y.} and Lee, {J. H.} and Levin, {V. A.}",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "1991",

month = jun,

doi = "10.1097/00001813-199106000-00007",

language = "English (US)",

volume = "2",

pages = "267--268",

journal = "Anti-cancer drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Inhibition of adenylate cyclase by tetraplatin.

AU - Ho, B. T.

AU - Huo, Y. Y.

AU - Lee, J. H.

AU - Levin, V. A.

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 1991/6

Y1 - 1991/6

N2 - In the investigation of effects of platinum-containing compounds on dopamine (DA)-activated adenylate cyclase system, tetraplatin and cisplatin were found to suppress the increase of enzyme activity by various activators. However, tetraplatin was a much more potent inhibitor than cisplatin, with its I50 values being 1/25, 1/45, and 1/130 that of cisplatin in the presence of DA/Gpp(NH)p, NaF/AlCl3, and forskolin/Gpp(NH)p respectively.

AB - In the investigation of effects of platinum-containing compounds on dopamine (DA)-activated adenylate cyclase system, tetraplatin and cisplatin were found to suppress the increase of enzyme activity by various activators. However, tetraplatin was a much more potent inhibitor than cisplatin, with its I50 values being 1/25, 1/45, and 1/130 that of cisplatin in the presence of DA/Gpp(NH)p, NaF/AlCl3, and forskolin/Gpp(NH)p respectively.

UR - http://www.scopus.com/inward/record.url?scp=0026167869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026167869&partnerID=8YFLogxK

U2 - 10.1097/00001813-199106000-00007

DO - 10.1097/00001813-199106000-00007

M3 - Article

C2 - 1802021

AN - SCOPUS:0026167869

SN - 0959-4973

VL - 2

SP - 267

EP - 268

JO - Anti-cancer drugs

JF - Anti-cancer drugs

IS - 3

ER -

Inhibition of adenylate cyclase by tetraplatin.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this